Sebia partners with Inserm Transfert to develop a unique diagnostic test for haemoglobin diseases
Collaboration will focus mainly on the diagnosis of thalassaemias
11-06-2012: Sebia announced that it has entered into partnership with Inserm (the French National Institute of Health and Medical Research) and Inserm Transfert, its private subsidiary responsible for marketing the outcomes of its scientific research, to develop and commercialize a unique biological test for measuring free alpha globin chains in beta-thalassaemic patients. The test will indicate the severity index of the disease in patients.
Negotiated by Inserm Transfert, the collaboration calls for Sebia to support the research carried out by Inserm, which will develop the test. In return, Sebia will have the possibility of acquiring exclusive rights to industrially develop and commercialize the test internationally.
The test for quantifying alpha globin chains was developed by unit U779 along with the participation of the research team of Professor Frédéric Galactéros, who heads the red blood cell genetic disease unit at the Henri Mondor Hospital within the Paris Public Hospital Authority. According to Prof. Galactéros, the test Sebia and Inserm Transfert will develop will fill a gap in orienting the diagnosis of thalassaemic patients, since existing methods are more laborious, more costly, and are exclusively intended for research laboratories. Thus, it should result in the commercialization of a new test that does not use radioactivity, will provide a better appreciation of patients’ phenotypes, and will be better adapted to the monitoring of treatment. Furthermore, it will be suitable on a routine basis and available to all laboratories.
A preliminary study of this test has been carried out on 54 subjects (consisting of 20 patients suffering from beta-thalassaemia, 6 patients with alpha-thalassaemia, and a 28-reference control group). The phenotypes of the different haemoglobins were studied using high-performance liquid chromatography (HPLC) methods. This technique ensures an accurate measurement of foetal haemoglobin (HbF) and HbA2, the percentage of which is an important element for the diagnosis of thalassaemias. “HPLC and capillary electrophoresis separation techniques are valuable tools for identifying or confirming the presence of abnormal haemoglobins,” explains Véronique Baudin-Creuza.
Contact / Request information
Request further information free of charge:
- Inserm Transfert
- diagnostic tests
- 1Schleicher & Schuell has been purchased by Whatman plc
- 2analytica Vietnam 2013 – Platform for innovations
- 3Thermo Fisher Scientific to Acquire Life Technologies Corporation
- 4Inspecting water quality with Raman spectroscopy
- 5LIMS/LIS Market and POCT Supplement
- 6X-ray analysis could boost legumes, thus reducing fertilizer pollution
- 7Analytik Jena announces forecast for financial year 2012/2013
- 8Abbott Completes Acquisition of Advanced Medical Optics
- 9Troubling levels of toxic metals found in lipstick
- 10Genzyme Launches New Diagnostic Test for Common Blood Cancer
- Malvern Instruments announces global agreement with Proveris Scientific
- Evonik selects OPX Biotechnologies for joint development of bio-based chemicals
- Agilent Technologies Collaborating with Florida International University to ...
- Almac and TTP Labtech form alliance in fluorescence lifetime technology
- Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco ...
- 450-year-old metal analysed at the nanometre level for finer detail of corrosion mechanism
- Novasep invests EUR 30 million to build world's largest chromatography plant for the pharmaceutical industry
- Eurofins completes 2012 Laboratory Expansion Plan
- Sebia partners with Inserm Transfert to develop a unique diagnostic test for haemoglobin diseases
- Takara Bio Europe Goes Direct in 2012